Chartwell RX LLC, a pharmaceutical company based in Congers, New York, was awarded a single-award Indefinite Delivery Contract (IDC) valued at over $7 million by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, which runs through March 2030, enables Chartwell RX to manufacture and distribute a broad spectrum of medications, including oral antibiotics, antivirals, antiemetics, and antifungals, to support healthcare services for military personnel, veterans, and other government beneficiaries. Additionally, Chartwell RX holds a Federal Supply Schedule contract with the Department of Veterans Affairs, valued at up to $225,000 through October 2025, for the provision of pharmaceuticals and hematology-related products.
Under the DLA IDC, Chartwell RX has received numerous delivery orders to supply a variety of pharmaceutical products, such as ondansetron orally disintegrating tablets, valacyclovir hydrochloride tablets, doxycycline hyclate tablets, and linezolid tablets. These orders, which do not have set-aside designations, are firm fixed-price contracts with ultimate completion dates ranging from 2024 to 2030. Chartwell RX has also been awarded a $139.7 million small business set-aside contract from the Department of Health and Human Services to provide doxycycline hyclate tablets and amoxicillin trihydrate capsules for the Strategic National Stockpile, further demonstrating the company's capabilities in supporting government healthcare needs.
Generated 1/1/25, 12:10 AM